{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:07:59Z","timestamp":1789967279972,"version":"4.0.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cervical clear cell carcinoma (CCC) is a rare and aggressive subtype of cervical adenocarcinoma whose molecular drivers and therapeutic vulnerabilities remain incompletely defined. As a key component of the SWI\/SNF chromatin-remodeling complex, ARID1A has been recognized as a potential biomarker of therapeutic response across multiple human malignancies. Nevertheless, the molecular and clinical significance of ARID1A in CCC has not been systematically clarified. This study aimed to characterize the genomic landscape of CCC and explore whether ARID1A deficiency serves as a molecular signature that confers actionable therapeutic vulnerabilities for precision oncology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively collected clinicopathological data from 27 patients diagnosed with CCC at Sun Yat-sen University Cancer Center between August 2018 and May 2023. Targeted next-generation sequencing (NGS) was performed using a cancer-related panel with complete exon coverage of 312 genes and selected-region coverage of additional cancer-associated genes in tumor tissues and matched peripheral blood samples from 7 patients to identify recurrent genomic alterations and perturbed biological pathways. Functional enrichment analyses, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein\u2013protein interaction (PPI) network analyses, were conducted to identify altered pathways and candidate hub genes. Based on the integrated genomic and network analyses, ARID1A was selected for further evaluation, and ARID1A protein expression was evaluated by immunohistochemistry in 27 CCC samples and 30 HPV-associated cervical adenocarcinoma (HPVA) samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median age of enrolled patients was 47.6 years, and 74.1% of patients presented with early-stage disease (FIGO IA\u2013IIA). With a median follow-up duration of 44.6 months, the 3- and 5-year overall survival rates were 90% and 77%, respectively. Targeted NGS identified a total of 93 somatic alterations spanning 78 genes, with recurrent alterations predominantly occurring in ARID1A, PIK3CA, SMARCA4, and JAK3. Pathway enrichment revealed significant perturbations in chromatin-remodeling, PI3K-AKT, p53, and JAK-STAT signaling pathways. PPI network analysis identified ARID1A, PIK3CA, EGFR, and CTNNB1 as core hub molecules mediating tumorigenesis. Complete loss of nuclear ARID1A expression was detected in 51.8% of CCC cases, significantly higher than the 6.0% rate detected in HPVA lesions (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CCC exhibits a distinct molecular profile characterized by frequent disruption of chromatin-remodeling pathways. Enrichment analyses linked ARID1A deficiency to concurrent genomic aberrations affecting chromatin remodeling and PI3K\/AKT cascades. Our findings suggest that ARID1A loss could act as a potential adjunctive diagnostic marker when interpreted together with histopathological features, HPV status, and other immunohistochemical markers, while representing a therapeutic vulnerability requiring further validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1943760","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:29:15Z","timestamp":1789964955000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["ARID1A deficiency identifies molecular alterations and potential therapeutic implications in cervical clear cell carcinoma: an integrated genomic and clinicopathological study"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaoni","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Pathology, Shenzhen People\u2019s Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[{"name":"Mental Rehabilitation Department, Shenzhen Mental Health Center, Shenzhen Kangning Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shenzhen Third People\u2019s Hospital, The Second Affiliated Hospital of Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huirong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Rare Diseases, The University of Hong Kong-Shenzhen Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shenzhen People\u2019s Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shenzhen People\u2019s Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaipeng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shenzhen Third People\u2019s Hospital, The Second Affiliated Hospital of Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shenzhen Third People\u2019s Hospital, The Second Affiliated Hospital of Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshi","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shenzhen Third People\u2019s Hospital, The Second Affiliated Hospital of Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shenzhen People\u2019s Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Molecular Diagnostics, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000986","article-title":"International endocervical adenocarcinoma criteria and classification (IECC): A new pathogenetic classification for invasive adenocarcinomas of the endocervix","volume":"42","author":"Stolnicu","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2017.02.008","article-title":"Clear cell adenocarcinoma of the cervix in second generation young women who are without maternal exposure to diethylstilbestrol: A case report","volume":"20","author":"Tantitamit","year":"2017","journal-title":"Gynecol Oncol Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197104222841604","article-title":"Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women","volume":"284","author":"Herbst","year":"1971","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.02.007","article-title":"Clear cell carcinoma of the cervix: A multi-institutional review in the post-DES era","volume":"109","author":"Thomas","year":"2008","journal-title":"Gynecol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1999.5700","article-title":"Clear cell carcinoma of the uterine cervix: Pathology and prognosis in surgically treated stage IB-IIB disease in women not exposed in utero to diethylstilbestrol","volume":"76","author":"Reich","year":"2000","journal-title":"Gynecol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001863","article-title":"Clear cell carcinoma (CCC) of the cervix is a human papillomavirus (HPV)-independent tumor associated with poor outcome: A comprehensive analysis of 58 cases","volume":"46","author":"Stolnicu","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7292(95)90992-w","article-title":"Human papillomavirus detection and p53 expression in clear-cell adenocarcinoma of the vagina and cervix","volume":"84","author":"Waggoner","year":"1994","journal-title":"Obstet Gynecol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw227","article-title":"VarDict: A novel and versatile variant caller for next-generation sequencing in cancer research","volume":"44","author":"Lai","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182981bdc","article-title":"Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma","volume":"23","author":"Ueno","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/ng.2628","article-title":"Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human Malignancy","volume":"45","author":"Kadoch","year":"2013","journal-title":"Nat Genet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.1196333","article-title":"Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma","volume":"330","author":"Jones","year":"2010","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05471-x","article-title":"Explore the alterations of downstream molecular pathways caused by ARID1A mutation\/knockout in human endometrial cancer cells","volume":"149","author":"Xing","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2021.12.002","article-title":"Endocervical neoplasia: Pathologic updates in diagnosis and prognosis","volume":"39","author":"Rivera-Col\u00f3n","year":"2022","journal-title":"Semin Diagn Pathol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/2159-8290.CD-12-0361","article-title":"ARID1A mutations in cancer: Another epigenetic tumor suppressor","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.07.026","article-title":"Remodeling of the ARID1A tumor suppressor","volume":"491","author":"Luo","year":"2020","journal-title":"Cancer Lett"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2739\/kurumemedj.MS6934018","article-title":"Comprehensive molecular profiling and clinicopathological characteristics of gastric-type mucinous carcinoma of the uterine cervix in Japanese women","volume":"69","author":"Nasu","year":"2024","journal-title":"Kurume Med J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgv115","article-title":"Patterns of somatic uniparental disomy identify novel tumor suppressor genes in colorectal cancer","volume":"36","author":"Torabi","year":"2015","journal-title":"Carcinogenesis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/path.5910","article-title":"Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix","volume":"257","author":"Kim","year":"2022","journal-title":"J Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cells8070678","article-title":"ARID1A mutations are associated with increased immune activity in gastrointestinal cancer","volume":"8","author":"Li","year":"2019","journal-title":"Cells"},{"key":"B21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10020-020-00208-9","article-title":"Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer","volume":"26","author":"Sun","year":"2020","journal-title":"Mol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202204951","article-title":"Single-cell landscape highlights heterogenous microenvironment, novel immune reaction patterns, potential biomarkers and unique therapeutic strategies of cervical squamous carcinoma, human papillomavirus-associated (HPVA) and non-HPVA adenocarcinoma","volume":"10","author":"Qiu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.humpath.2018.04.003","article-title":"Loss of ARID1A expression is associated with poor prognosis in patients with gastric cancer","volume":"78","author":"Zhu","year":"2018","journal-title":"Hum Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i48.18404","article-title":"Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer","volume":"20","author":"Wei","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.07.003","article-title":"ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder","volume":"45","author":"Faraj","year":"2014","journal-title":"Hum Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322660","article-title":"Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency","volume":"71","author":"Dong","year":"2022","journal-title":"Gut"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms140918824","article-title":"ARID1A mutations and PI3K\/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas","volume":"14","author":"Samartzis","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-120","article-title":"A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: Protein expression is histotype-specific and loss of ARID1A\/BAF250a is associated with AKT phosphorylation","volume":"14","author":"Wiegand","year":"2014","journal-title":"BMC Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13045-018-0674-5","article-title":"The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the \u03b2-catenin\/SIRT3 signaling pathway in cervical cancer","volume":"11","author":"Jiang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22262","article-title":"Cancer risks for MLH1 and MSH2 mutation carriers","volume":"34","author":"Dowty","year":"2013","journal-title":"Hum Mutat"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19040979","article-title":"Lynch syndrome-related clear cell carcinoma of the cervix: A case report","volume":"19","author":"Nakamura","year":"2018","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1943760\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:29:15Z","timestamp":1789964955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1943760\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1943760"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1943760","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1943760"}}